Compare iShares Core High Dividend ETF (HDV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares Core High Dividend ETF trades at $29.04, while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| HDV | IDXX | |
|---|---|---|
52-Week High | $29.14 | $766.68 |
52-Week Low | $23.64 | $526.44 |
Market Cap | — | $46.22B |
Sector | — | Health |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.07, up 0.28% with strong bullish technical signals from moving averages. The ETF focuses on high-quality US large-cap dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying activity from firms like Bay Colony Advisors and 180 Wealth Advisors indicates growing confidence in the fund's income-generating strategy.
The outlook remains positive given HDV's defensive sector weighting and quality screening methodology. Key risks include interest rate sensitivity and market volatility affecting dividend sustainability. Wall Street sentiment is constructive as the ETF continues to attract retirement-focused investors seeking reliable income streams in the current economic environment.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
